Cargando…
Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe form of idiopathic interstitial pneumonias. Although IPF has not been thought to be associated with bacterial communities, recent papers reported the possible role of microbiome composition in IPF. The roles of microbiom...
Autores principales: | Takahashi, Youhei, Saito, Atsushi, Chiba, Hirofumi, Kuronuma, Koji, Ikeda, Kimiyuki, Kobayashi, Tomofumi, Ariki, Shigeru, Takahashi, Motoko, Sasaki, Yasushi, Takahashi, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389110/ https://www.ncbi.nlm.nih.gov/pubmed/29486761 http://dx.doi.org/10.1186/s12931-018-0736-9 |
Ejemplares similares
-
Insufficient serum L-ficolin is associated with disease presence and extent of pulmonary Mycobacterium avium complex disease
por: Kobayashi, Tomofumi, et al.
Publicado: (2019) -
Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis
por: Nishikiori, Hirotaka, et al.
Publicado: (2014) -
Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
por: Shioya, Makoto, et al.
Publicado: (2018) -
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020) -
Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)